- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02036099
Driving in Mild Dementia Decision Tool (DMD-DT)
February 5, 2021 updated by: Sunnybrook Health Sciences Centre
Based on the literature on dementia and driving, and on knowledge tools available to date including one from our current work, a Driving in Mild Dementia Decision Tool (DMD-DT) will be adapted and tailored to guide physicians in their decisions to report a driver with mild dementia to the provincial licensing agency.
The DMD-DT intervention will include a) an algorithm-based computerized clinical decision support system (CCDSS) for facilitating driving assessment and physicians' reporting to provincial transportation authorities, b) an individualized educational package for patients and caregivers about dementia and driving and driving cessation, and c) a modified reporting form to provincial driving regulatory authorities.
Months 1 to 6: The DMD-DT will be tailored and adapted to practice with the input of the co-investigators and knowledge-users who represent the perspectives of physicians, patients and their caregivers, as well as transportation authorities.
Pilot testing will be done, and input from focus groups of knowledge-users will refine the intervention.
Physicians will be recruited to participate in a clinical trial of the DMD-DT.
Months 7-18: A parallel-group cluster randomized controlled trial (RCT) will be conducted to compare the effects of the DMD-DT to a legislation reminder on recommendations for reporting to the licensing agency.
The effects of the DMD-DT on the doctor-patient relationship will be further explored in focus groups and interviews with physicians.
Months 19-24: The knowledge obtained from the study will be used to generalize and sustain use of the intervention beyond Ontario, Canada, and to disseminate the information to knowledge-users.
The primary outcome measure is the filing of a report to the Ministry of Transportation of Ontario, indicating that the physician has a concern about the patient's health condition (i.e.
mild dementia).
The primary outcome of the study is the difference in reporting between the DMD-DT and control arms.
Since the current reporting rate is low, approximately 13%, from a public health point of view, the primary outcome expected is that physicians in the DMD-DT group will report more patients with mild dementia than those in the control group.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
as above
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- family physicians and specialist physicians (geriatricians, geriatric psychiatrists, cognitive neurologists) practicing in Ontario, Canada, who assess and treat patients with mild dementia
- must speak English and have computer access at the point of delivery of care
Exclusion Criteria:
- family physicians must see at least 10 new patients per year with mild dementia, and specialist physicians must see at least 12 new patients per year with mild dementia
- participants must not have participated in, attended a continuing medical education (CME) event about, or read about our "Dementia and Driving in Ontario" study (2010-2012)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intervention
Participants in this arm will assess patients using the Driving in Mild Dementia Decision Tool.
|
|
|
NO_INTERVENTION: Control
Participants in this arm will assess patients using their usual care strategies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients reported to the Ontario Ministry of Transportation
Time Frame: When participants have completed 500 patient assessments (expected to take approximately 12 months)
|
The primary outcome of this study is the number of patients reported to the Ontario Ministry of Transportation by study participants.
A "report" indicates that the participant believes his/her patient may be unsafe to continue driving due to mild cognitive impairment or mild dementia.
The difference in the number of reports filed between the intervention and control group participants will be assessed.
|
When participants have completed 500 patient assessments (expected to take approximately 12 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of "false positives", i.e. number of patients reported to the Ontario Ministry of Transportation as potentially being unsafe drivers who are deemed by expert consensus to be safe drivers.
Time Frame: When participants have completed 500 patient assessments (expected to take approximately 12 months)
|
Although the primary aim of the study from a public health point of view is to increase reporting of patients with mild dementia to transportation authorities who are unsafe to drive according to best-evidence, it is important to ensure that physician reporting does not unfairly punish those who are deemed not to be at significant potential risk.
Hence, a secondary outcome measure will examine the number of false positive reports, or the number of patients reported when expert consensus indicates they should NOT be reported.
|
When participants have completed 500 patient assessments (expected to take approximately 12 months)
|
|
Number of recommendations given for specialized on-road testing
Time Frame: When participants have completed 500 patient assessments (expected to take approximately 12 months)
|
International guidelines suggest that when physicians are uncertain about the driving safety of their patients, specialized on-road testing should be strongly considered.
Such testing, while expensive, has substantially more face validity than in-office testing.
A secondary outcome measure for this study is therefore the number of recommendations made by participants for specialized on-road testing for the patients assessed in the study.
|
When participants have completed 500 patient assessments (expected to take approximately 12 months)
|
|
Quality of Doctor-Patient Relationship
Time Frame: When participants have completed 500 patient assessments (expected to take approximately 12 months)
|
Many physicians avoid discussing issues related to driving with their patients who have mild dementia and their caregivers or family members, because it can have a negative effect on the doctor-patient relationship.
The impact of the Driving in Mild Dementia Decision Tool on the doctor-patient relationship will be examined in two ways: first, by comparing responses between intervention and control group participants on four 5-point Likert-type questions following each patient encounter; and second, by analyzing transcripts from focus groups with participants following completion of the trial.
|
When participants have completed 500 patient assessments (expected to take approximately 12 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Mark J Rapoport, MD, Sunnybrook Health Sciences Centre
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (ACTUAL)
January 1, 2016
Study Completion (ACTUAL)
January 1, 2016
Study Registration Dates
First Submitted
January 3, 2014
First Submitted That Met QC Criteria
January 13, 2014
First Posted (ESTIMATE)
January 14, 2014
Study Record Updates
Last Update Posted (ACTUAL)
February 10, 2021
Last Update Submitted That Met QC Criteria
February 5, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KAL129896
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
Benjamin Rose Institute on AgingNational Institute on Aging (NIA)RecruitingMild Dementia | Moderate DementiaUnited States
-
Yaolin PeiNational Institutes of Health (NIH)RecruitingEnd of Life Decision Making | Dementia Caregivers | Advanced DementiaUnited States
-
Benuvia Therapeutics Inc.MandaraNot yet recruiting
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityCompletedDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeActive, not recruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityCompletedDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
The University of Hong KongNot yet recruiting
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
Clinical Trials on Driving in Mild Dementia Decision Tool
-
University of North Carolina, Chapel HillNational Institute of Nursing Research (NINR)Completed
-
M.D. Anderson Cancer CenterMerck Sharp & Dohme LLCRecruiting
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR)RecruitingSepsis | Bacterial Infections | Community-Acquired Infections | Hospital InfectionCanada
-
Barcelona Institute for Global HealthUniversidad de Granada; Consorci d'Atenció Primària de Salut de l'Eixample; Hospital... and other collaboratorsCompletedHepatitis B | Hepatitis C | Tuberculosis | Hiv | Chagas Disease | Schistosomiasis | Strongyloidiasis | Female Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III StatusSpain
-
Central Hospital, Nancy, FranceRecruitingPeripheral Venous AccessFrance
-
University of Illinois at ChicagoNational Cancer Institute (NCI); Rush University Medical CenterCompletedColorectal CancerUnited States